Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 462
- Registration Number
- NCT02289352
- Locations
- 🇺🇸
Investigator site 2, Hot Springs, Arkansas, United States
🇺🇸Investigator site 16, Long Beach, California, United States
🇺🇸Investigator site 5, Miami, Florida, United States
A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 893
- Registration Number
- NCT02267746
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸Moore Clinical Research, Tampa, Florida, United States
🇺🇸LCC Medical Research Institute, Miami, Florida, United States
A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
- Conditions
- BACTERIAL VAGINOSISVaginal Discharge Color, Odor, and ConsistencyVulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or SevereVulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or SevereSigns and Symptoms to be Evaluated and Recorded Include
- Interventions
- Other: placebo
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 604
- Registration Number
- NCT02210689
- Locations
- 🇺🇸
Akesis Investigator site 5, Birmingham, Alabama, United States
🇺🇸Akesis Investigator site 12, La Mesa, California, United States
🇺🇸Akesis investigator site 6, San Diego, California, United States
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1009
- Registration Number
- NCT02120924
- Locations
- 🇺🇸
Site 24, Fremont, California, United States
🇺🇸Site 22, Santa Monica, California, United States
🇺🇸Site 1, Brandon, Florida, United States
A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 467
- Registration Number
- NCT02120898
- Locations
- 🇺🇸
Site 1, Birmingham, Alabama, United States
🇺🇸Site 10, Fremont, California, United States
🇺🇸Site 8, Los Angeles, California, United States
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT01962987
- Locations
- 🇺🇸
Investigator Site 23, Fremont, California, United States
🇺🇸Investigator Site 9, Long Beach, California, United States
🇺🇸Investigator Site 12, Newport Beach, California, United States
Clinical Equivalence Study of Mometasone Nasal Spray
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: placebo
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT01850823
- Locations
- 🇺🇸
Investigator site 18, Stockbridge, Georgia, United States
🇺🇸Investigator site 1, Louisville, Kentucky, United States
🇺🇸Investigator site 3, Bethesda, Maryland, United States
Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: Test product (B) ExemestaneDrug: Reference product (A) Aromasin (Exemestane)
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Actavis Inc.
- Registration Number
- NCT01760980
- Locations
- 🇿🇦
Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa
Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2010-08-30
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01190761
- Locations
- 🇨🇦
SFBC Anapharm, Sainte-Foy, Quebec, Canada
Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01190748
- Locations
- 🇨🇦
SFBC Anapharm, Sainte-Foy, Quebec, Canada